Latest Conference

This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.

In the primary efficacy analysis, the risk of developing symptomatic COVID 19 was reduced by 77% with AZD7442.

The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.

A survey found most healthcare professionals would clear an asymptomatic patient with a positive PCR test if the patient met other criteria.

In a study looking at one urban South Florida hospital, the pandemic negatively impacted testing.

A study found disproportionately higher COVID-19 cases in Black and Hispanic people with HIV across the US.

A study’s findings support the use of the therapy earlier in the course of COVID-19 in hospitalized patients.

Orange County, CA nursing homes that partook in either universal decolonization or prevention training had significantly fewer staff and resident COVID-19 cases than nursing homes that did not.

During the pandemic, hospitalists prescribing patterns changed, reflecting new data, clinical experience, and the introduction of new therapies.

Investigators saw vastly higher rates of hospitalization and mortality for rural populations over urban even after adjusting the results for various factors.

The Infectious Diseases Society of America’s (IDSA) 2017 guideline saw an increase in using vancomycin as a first line therapy for Clostridioides difficile (CDI).

Rates of Sexually Transmitted Infections (STIs) and engagement in HIV pre-exposure prophylaxis during the COVID-19 pandemic were previously unknown, but one IDWeek study examined these data trends over the past few years.

An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.

Pre-exposure prophylaxis (PrEP) is safe and effective for preventing HIV when used correctly, but this information is not as well-known as it should be, new study finds.

A team from a tertiary center in the Middle East used a multidisciplinary approach to increase immunization.

In research presented virtually at IDWeek 2021, investigators with the Centers for Disease Control and Prevention (CDC) conducted a review of nursing home antibiotic stewardship citation deficiencies in order to improve implementation.

In newly hospitalized hypoxic patients with COVID-19, the monoclonal antibody significantly improved survival without invasive mechanical ventilation compared with placebo and available treatments, according to phase 3 trial results.

Ferring is presenting data from five studies at this week’s IDWeek about its investigational biotherapeutic, RBX2660, being studied for this problematic bacterium.

“Compared to the pre-COVID period, the odds ratio for CVD encounters was nearly doubled in each post-COVID period from 31 to 90 days post onset,” Brian Agan, MD, deputy science director and HIV research director of the Infectious Disease Clinical Research Program at USU/HJF and presenting author, told Contagion®.

A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.

The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.

Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

Impaired resilience was found to be associated with loneliness.

Virtual support services were crucial for providing continued care and education.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.

Many respondents reported having a lack of information about the use of PrEP.